cytochrome P450 family 4 subfamily F member 26, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4F26P profile across patient tissues and cancer cell-line models. CYP4F26P expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP4F26P is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, CYP4F26P RNA expression shows 13,842 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where CYP4F26P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4F26P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4F26P survival associations across molecular data types. CYP4F26P RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4F26P RNA expression–survival associations across cancer types. High CYP4F26P expression shows unfavorable associations in KIRC, MESO, ACC and LUAD, but favorable associations in UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP4F26P RNA expression.
This table summarizes CYP4F26P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4F26P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4F26P shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in KIRP, LUSC and CHOL. The KIRP box plot shows higher CYP4F26P RNA expression in tumor versus normal tissue (log2 FC = +0.248, t-test p = .007).
This table shows molecular features associated with CYP4F26P in patient tissues and cancer cell lines. In patient samples, CYP4F26P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
